NKL-001 / NKILT Therap - LARVOL DELTA

NKILT Therapeutics announces oral presentation featuring Chimeric ILT-Receptor (CIR) engineered NK cells at the 65th ASH Annual Meeting and poster presentation at the 38th SITC Annual Meeting (PRNewswire) - "NKILT Therapeutics, Inc...announced today that preclinical data of the CIR™NK cells have been selected for an oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, being held December 9-12, 2023, and for poster presentation at the 38th Society of Immunotherapy for Cancer (SITC) Annual Meeting, being held November 1-5, 2023...The ASH 2023 oral presentation will feature details of the proprietary activation domains that enhance activity of the CIR™NK engineered cells against HLA-G-positive acute myeloid leukemia (AML) cells. This presentation will expand preclinical data with a specific focus on these novel activation domains and will characterize the serial killing activity against AML cells...'Today's poster presentation....confirm the great progress we have made in the development of our unique engineered CIR™NK cells, which allows us to remain on track to name our lead assets to launch our IND process later this year.'"

IND • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology